Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation

NCT05009329 is registered in ClinicalTrials.gov with Allist Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05009329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05009329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation
Lead sponsor
Allist Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 26, 2021
Completion date
December 31, 2026
Enrollment
315 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, solid tumor